Psilocybin-assisted psychotherapy trial in treatment-resistant depression maps antidepressant response, acute subjective effects, and baseline predictors

Psilocybin-assisted psychotherapy in treatment-resistant depression is the central focus of this Nature Molecular Psychiatry paper. The study examines antidepressant outcomes alongside acute subjective effects and baseline factors that may predict who benefits most, linking clinical change to the psychedelic experience rather than treating symptom reduction in isolation. Treatment-resistant depression provides the clinical context, with outcome measures centered on changes in depressive symptoms after guided psilocybin sessions embedded in psychotherapy. Acute experiential variables appear to be analyzed as potential mediators or correlates of improvement, while baseline characteristics are evaluated for their predictive value in stratifying response. Psilocybin research matters here because it connects efficacy, mechanism, and patient selection in one framework. That combination can inform future trial design, help refine therapeutic protocols, and support a more precise understanding of which patients may benefit, under what conditions, and through which experiential pathways.